GLP-1s Educational Guide

Section 08

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone produced primarily by L-cells in the small intestine in response to food intake. Its physiological role is to coordinate the body's postprandial (after-meal) metabolic response through several simultaneous mechanisms: stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner (meaning it only triggers insulin release when blood glucose is elevated, reducing the risk of hypoglycemia), suppressing glucagon secretion (the hormone that raises blood glucose), slowing gastric emptying to moderate the rate at which nutrients enter the bloodstream, and signaling the hypothalamus to promote satiety and reduce appetite. These combined effects make GLP-1 a powerful regulator of glucose homeostasis and energy intake.

GLP-1 receptor agonists (GLP-1 RAs) are synthetic compounds engineered to mimic and extend the activity of endogenous GLP-1, which has a very short half-life in the body (approximately two minutes). Current FDA-approved agents include semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for obesity management) and tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity), the latter acting as a dual agonist at both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. These medications are administered by subcutaneous injection on a weekly schedule and are titrated gradually to minimize gastrointestinal side effects.

It is important to understand what GLP-1 receptor agonists are not. They are not stimulants. They do not act on the sympathetic nervous system, do not raise heart rate or blood pressure through adrenergic mechanisms, and do not cause the agitation, dependency, or cardiovascular strain associated with appetite-suppressing stimulants. Their weight-reducing effect operates primarily through central satiety signaling and reduced caloric intake — not through metabolic acceleration. This distinction matters clinically and for how women contextualize their experience on these medications.

Section 09

GLP-1s and Women's Metabolic Health

The metabolic environment of perimenopause and menopause is not simply a backdrop against which GLP-1 medications operate — it is a variable that actively shapes how women respond to these therapies. Declining estrogen drives a coordinated shift in body composition: preferential accumulation of visceral adipose tissue (fat deposited around abdominal organs), reduction in lean muscle mass, slowing of basal metabolic rate, and increasing peripheral and hepatic insulin resistance. This constellation of changes makes postmenopausal women biologically predisposed to weight gain even in the absence of changes in dietary behavior, and makes weight loss through diet and exercise alone progressively more challenging.

GLP-1 receptor agonists address several of these menopausal metabolic changes simultaneously. By reducing appetite and caloric intake, improving insulin sensitivity, and promoting fat utilization, they engage the precise mechanisms that estrogen withdrawal had disrupted. Emerging clinical data — including a 2024 study published in Menopause (Salamun et al.) — found that semaglutide produced significant weight loss in postmenopausal women, with greater response observed in women who were also receiving menopausal hormone therapy, suggesting a potential synergy between estrogen exposure and GLP-1 receptor signaling in hypothalamic appetite circuits. This finding is biologically plausible: preclinical studies have demonstrated that estrogen receptor activation and GLP-1 receptor agonism influence overlapping hypothalamic pathways governing food intake and energy balance.

Research on body composition outcomes in women on GLP-1 therapy raises an important concern: a significant proportion of weight lost during GLP-1 therapy can include lean muscle mass, not only fat. In postmenopausal women — who already face age-related and estrogen-mediated sarcopenia — this risk is amplified. A 2025 study examining semaglutide in menopausal women emphasized that preserving skeletal muscle mass and function should be considered a central therapeutic target, not a secondary consideration. This finding reinforces the critical importance of structured resistance training and adequate protein intake throughout GLP-1 treatment, both of which are addressed in the nutritional support section that follows.

Clinical Consideration

Women using GLP-1 medications in the context of perimenopause or menopause should discuss their hormonal status with their prescribing provider. The intersection of hormone therapy, menopausal physiology, and GLP-1 pharmacology is an emerging and clinically relevant area that warrants individualized assessment.

Section 10

Gut Health Considerations on GLP-1 Therapy

GLP-1 receptors are expressed not only in the pancreas, brain, and heart — they are distributed throughout the gastrointestinal tract itself. GLP-1 receptor agonists therefore have direct and measurable effects on gut physiology, which is clinically important for women who are simultaneously managing gut health as part of their broader menopausal health strategy.

The most significant GI effect of GLP-1 RAs is delayed gastric emptying: the medication slows the rate at which food moves from the stomach into the small intestine. This effect is the mechanistic basis for the profound satiety these medications produce — a woman eating a smaller meal feels full quickly and remains satisfied longer because gastric emptying is prolonged. However, the same mechanism underlies the most common adverse effects: nausea, vomiting, bloating, and constipation. These are experienced primarily during dose escalation phases and typically diminish over time, though they can be significant barriers to tolerability in the early weeks of treatment.

Emerging research has also examined GLP-1 medications' effects on the gut microbiome. Preclinical studies and early human data suggest that GLP-1 RAs may alter microbial composition — some research suggesting increases in Akkermansia muciniphila, a species associated with gut barrier integrity and metabolic health. However, the research in this area is still preliminary and the clinical significance of microbiome shifts on GLP-1 therapy in women is not yet established. What is clear is that the slowing of gut motility, combined with reduced food intake and potentially altered microbial substrate availability, creates a gut environment that benefits from deliberate nutritional support.

Practical strategies to support gastrointestinal tolerability and gut health during GLP-1 therapy include: consuming smaller, more frequent meals rather than large meals that overwhelm slowed gastric emptying; maintaining adequate hydration (which supports motility and reduces constipation risk); timing fiber intake thoughtfully — high-fiber foods are important for microbial health but large fiber loads immediately before or after injection can worsen bloating; and avoiding high-fat meals, which significantly slow gastric emptying further and amplify nausea. The incorporation of prebiotic fibers (from sources such as garlic, leeks, oats, and green bananas) and probiotic-containing foods or supplements can help maintain microbial diversity in the context of reduced dietary variety and altered motility.

Section 11

Nutritional Support During GLP-1 Use

Because GLP-1 receptor agonists significantly reduce appetite and caloric intake, women using these medications face a nutritional challenge that is easy to overlook: eating less food means having fewer opportunities to meet protein, micronutrient, and fiber needs. Without deliberate attention to dietary quality, reduced food volume can result in nutritional deficiencies that undermine the very health goals the medication is meant to support.

Protein is the most critical nutritional priority during GLP-1 therapy, particularly in menopausal women who are already at risk for sarcopenia. Current evidence supports a minimum protein target of approximately 0.7 to 1.0 grams of protein per pound of ideal body weight per day to preserve lean muscle mass during caloric restriction. For a woman with an ideal body weight of 140 pounds, this translates to 98 to 140 grams of protein daily — a target that requires intentionality when total food volume is substantially reduced. A food-first approach is recommended: prioritizing high-quality protein sources such as eggs, Greek yogurt, cottage cheese, poultry, fish, legumes, and lean meats at every meal, before filling remaining caloric space with vegetables, fats, and complex carbohydrates.

Micronutrient considerations deserve equal attention. Several nutrients are at particular risk of inadequacy during GLP-1-mediated caloric restriction:

Scroll the table horizontally to compare every column.

Meal structure recommendations during GLP-1 therapy center on nutrient density — every meal and snack should carry meaningful nutritional value. Protein anchors each meal; non-starchy vegetables provide fiber, micronutrients, and polyphenols; whole food fats (avocado, olive oil, nuts) provide satiety and fat-soluble vitamin absorption; complex carbohydrates such as legumes, sweet potato, and whole grains are included in amounts appropriate to energy needs. Processed foods — which deliver caloric density with poor micronutrient return — become particularly costly in the context of reduced food volume, and minimizing them is a practical priority rather than a moral one.

Section 12

Managing Common Side Effects

Nausea is the most frequently reported side effect of GLP-1 therapy and is experienced by a majority of women during the initial titration phase. Evidence-based management strategies include: eating more slowly and stopping before full satiety (the medication delays the stomach emptying signal, making it easy to overeat before fullness registers); consuming smaller portions more frequently rather than three large meals; avoiding reclining within two to three hours of eating; choosing cool, low-odor foods during peak nausea (cold proteins, bland carbohydrates); and incorporating ginger — available as fresh ginger in warm water, ginger tea, or capsule form — which has a meaningful evidence base for reducing nausea across multiple clinical contexts. If nausea is severe or persistent, a conversation with the prescribing provider about dose titration pace is always appropriate.

Constipation affects a substantial proportion of GLP-1 users and is a direct consequence of slowed gastric motility. Management is multimodal: adequate daily hydration (a minimum of 64–80 ounces of water, adjusted for body weight) is essential; magnesium glycinate at moderate doses (200–400 mg daily) supports bowel regularity without the urgency associated with osmotic laxatives; soluble fiber from sources such as flaxseed, chia seed, and psyllium (introduced gradually to minimize bloating) supports stool consistency and motility; and regular movement — particularly walking — supports peristalsis through musculoskeletal and autonomic mechanisms.

Fatigue in the early weeks of GLP-1 therapy often reflects a combination of caloric restriction, temporary carbohydrate restriction, and micronutrient inadequacy. Prioritizing sleep, monitoring iron and B12 levels, ensuring adequate caloric intake to support baseline metabolic function, and avoiding excessive caloric deficits (particularly in the first weeks of treatment) are the primary management strategies. Adrenal support — through sleep optimization, stress reduction, and appropriately timed physical activity — also supports energy regulation.

Hair thinning is reported by some women on GLP-1 therapy and is typically attributable to telogen effluvium — a stress-related hair cycle disruption triggered by rapid weight loss and caloric restriction, not by the medication itself. Adequate protein intake is the most evidence-supported prevention and recovery strategy; zinc and biotin supplementation may be supportive where dietary intake is insufficient, though biotin megadosing should be noted to interfere with certain thyroid and cardiac lab assays. Hair shedding related to telogen effluvium typically resolves within three to six months once the triggering stressor is addressed.

When to Contact Your Healthcare Provider

Seek prompt medical attention for: severe or persistent vomiting that prevents adequate hydration; upper abdominal pain radiating to the back (a potential sign of pancreatitis); vision changes; rapid heart rate; signs of allergic reaction; or any symptom that feels alarming. GLP-1 medications carry a boxed warning regarding a potential association with thyroid C-cell tumors in animal studies — women with a personal or family history of medullary thyroid carcinoma or MEN-2 should not use these medications.

Section 13

Long-Term Considerations and Off-Ramp Planning

One of the most important conversations in the GLP-1 space — and one that is frequently deferred — is what happens when a woman discontinues treatment. The research on this question is now sufficiently robust to answer clearly: weight recidivism is substantial and common. Studies following participants after discontinuation of semaglutide (including data from the STEP-4 trial) found that a significant proportion of weight lost was regained within one year of stopping the medication, particularly in the absence of established lifestyle behaviors. This is not a failure of willpower; it is the predictable consequence of removing a pharmacological intervention without having addressed the underlying metabolic and behavioral drivers of excess weight.

This finding has a constructive implication: the treatment window — the period during which GLP-1 therapy is actively reducing appetite and producing metabolic improvements — is an opportunity window. Women who use this period to build durable habits in resistance training, protein adequacy, sleep consistency, and stress management are not merely enhancing their on-medication results; they are constructing the metabolic infrastructure that supports outcomes after treatment ends. This framing shifts the therapeutic goal from weight loss to metabolic reprogramming, which is a meaningfully different and more durable objective.

There remain important long-term unknowns in the use of GLP-1 medications specifically in menopausal women. The interaction between GLP-1 therapy and menopausal hormone therapy over multi-year timescales has not been characterized. The effects of prolonged GLP-1 use on bone mineral density — already at risk in postmenopausal women — are not yet fully established, though some research suggests that weight loss-associated bone loss may occur independent of the medication. The long-term effects on gut microbiome diversity, muscle mass trajectory, and hormonal markers in postmenopausal women represent research gaps that will likely be addressed in the coming years as the scale of GLP-1 use generates larger longitudinal datasets.

Shared decision-making with a healthcare provider remains the cornerstone of responsible GLP-1 use. This includes ongoing monitoring of lean body mass through body composition assessment, regular micronutrient screening, bone density surveillance appropriate to menopausal status, and transparent, ongoing conversation about goals, expectations, and the eventual transition plan — whether that involves continued treatment, dose adjustment, or a planned discontinuation supported by established lifestyle habits.